Identifying in-market application of Pelargonium root extract EPs 7630 for the treatment of COVID-19: analysis of pharmacovigilance data

Introduction: Phytopharmaceutical products are successfully used for acute respiratory infections and may therefore be promising candidates for adjuvant symptomatic treatment of COVID-19. In vitro and clinical studies suggest that the proprietary Pelargonium sidoides DC. root extract EPs 7630 has an...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Frontiers in Pharmacology
المؤلفون الرئيسيون: Fathi Abdul Malek, Petra Funk
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Frontiers Media S.A. 2024-02-01
الموضوعات:
Pelargonium sidoides root extract (EPs 7630)
off-label use
case reports
COVID-19
spontaneous reporting
safety
الوصول للمادة أونلاين:https://www.frontiersin.org/articles/10.3389/fphar.2024.1335309/full

الانترنت

https://www.frontiersin.org/articles/10.3389/fphar.2024.1335309/full

مواد مشابهة